Poison Pill

The poison pill was invented in 1982 by Martin Lipton, a founding partner of the law firm Wachtell, Lipton, Rosen & Katz, in response to a wave of hostile takeovers that characterized the early 1980s. Lipton first deployed the idea for El Paso Company, a natural gas firm facing a hostile bid from Burlington Northern, as a way to give corporate boards time and leverage to negotiate better terms or reject unwanted bids entirely. The innovation spread rapidly: by the late 1980s, hundreds of major corporations had adopted poison pill provisions. The legal validity of the poison pill was upheld by the Delaware Supreme Court in the landmark 1985 case Moran v. Household International, which established that boards could adopt rights plans without prior shareholder approval.

The mechanics of a typical poison pill work as follows. The board of directors adopts a shareholder rights plan that grants existing shareholders the right to purchase additional shares at a significant discount, usually 50%, if any single entity acquires more than a specified threshold of the company's outstanding shares, typically 10% to 20%. When an acquirer crosses this threshold, the pill is triggered, and all shareholders except the acquirer can exercise their rights, massively diluting the acquirer's ownership percentage and making the takeover far more expensive. The mere existence of a poison pill usually deters hostile bidders from attempting an acquisition without first negotiating with the board.

One of the most notable uses of a poison pill came in PeopleSoft's defense against Oracle's hostile bid, launched in June 2003 at $16 a share, or about $5.1 billion. PeopleSoft's board argued that the offer undervalued the company and kept its shareholder rights plan in place, which Oracle challenged in the Delaware courts. Oracle eventually acquired PeopleSoft in December 2004 for $26.50 a share, or about $10.3 billion, after a protracted 18-month battle, roughly double its opening offer. More recently, in April 2022, Twitter adopted a poison pill with a 15% trigger after Elon Musk disclosed a 9.2% stake and made an unsolicited offer of $54.20 a share, though the board agreed to sell the company to Musk later that month.

Critics of poison pills argue that they entrench management and prevent shareholders from receiving premium offers for their shares. Activist investors and proxy advisory firms like Institutional Shareholder Services have long pushed back against poison pills, arguing that they shift power away from shareholders and toward boards that may be acting in their own self-interest rather than maximizing shareholder value. Studies have produced mixed evidence: some research finds that poison pills reduce the likelihood of a completed acquisition, potentially destroying value for shareholders, while other studies find that they increase the final acquisition price when a deal does occur, benefiting shareholders.

From a strategic perspective, the poison pill remains one of the most powerful tools in the corporate governance toolkit. Boards must balance the defensive benefits of maintaining negotiating leverage against the risk of appearing to obstruct value-creating transactions. The trend in recent years has been toward shorter-duration pills, typically one year rather than the traditional ten years, and lower trigger thresholds, reflecting both increased shareholder activism and evolving best practices in corporate governance. During the COVID-19 pandemic, more than 60 companies adopted poison pills between March and June 2020, some with trigger thresholds well below the traditional 20%, fearing that depressed stock prices made them vulnerable to opportunistic acquirers.